我們已在上線！進一步了解

GeoVax Labs

GOVX

市值 US$234萬

0.2383 USD

-0.0195

7.56%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

0.2350

-0.0033

1.38%

1天

-7.56%

5天

-20.57%

1個月

-41.19%

3個月

-72.62%

6個月

-80.63%

今年迄今

-95.4%

1年

-98.3%

5年

-99.98%

10年

-99.98%

關於： Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

員工： 19

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 0%

中性 0%

負面 0%

Zacks Investment Research

GeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

GeoVax Labs (GOVX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

GeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

GeoVax Labs, Inc. (GOVX) Discusses Building a Resilient Infectious Disease Preparedness Strategy Focused on Ebola, Marburg, Hantavirus, and Mpox Transcript

GeoVax Labs, Inc. (GOVX) Discusses Building a Resilient Infectious Disease Preparedness Strategy Focused on Ebola, Marburg, Hantavirus, and Mpox Transcript

GeoVax Labs, Inc. (GOVX) Discusses Building a Resilient Infectious Disease Preparedness Strategy Focused on Ebola, Marburg, Hantavirus, and Mpox Transcript

GeoVax Stock Higher As Company Highlights MVA Platform For Ebola Threats

GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotech company, is trading higher on Wednesday as investors assess the company's recent financing deal alongside growing attention on its vaccine platform developments.

GeoVax Stock Higher As Company Highlights MVA Platform For Ebola Threats

Zacks Investment Research

All You Need to Know About GeoVax Labs (GOVX) Rating Upgrade to Buy

GeoVax Labs (GOVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About GeoVax Labs (GOVX) Rating Upgrade to Buy

GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript

GeoVax Labs, Inc. ( GOVX ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants David Dodd - Chairman, President & CEO Mark Reynolds - CFO & Corporate Secretary John Sharkey - Vice President of Business Development Conference Call Participants Jonathan Aschoff - ROTH Capital Partners, LLC, Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Laura Suriel John Vandermosten - Zacks Investment Research, Inc. Presentation Operator Good afternoon, and welcome, everyone, to the GeoVax Third Quarter 2025 Corporate Update Call. My name is Sherry, and I will facilitate today's call.

GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript

Zacks Investment Research

GeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock?

GeoVax Labs (GOVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock?

The Motley Fool

GeoVax Labs Revenue Doubles in Q2

GeoVax Labs Revenue Doubles in Q2

GeoVax Labs Revenue Doubles in Q2

GeoVax Labs, Inc. (GOVX) Q2 2025 Earnings Call Transcript

GeoVax Labs, Inc. (NASDAQ:GOVX ) Q2 2025 Earnings Conference Call July 28, 2025 4:30 PM ET Company Participants David Alan Dodd - Chairman, President & CEO John W. Sharkey - Vice President of Business Development Kelly T.

GeoVax Labs, Inc. (GOVX) Q2 2025 Earnings Call Transcript

GeoVax Labs, Inc. (GOVX) Q1 2025 Earnings Call Transcript

GeoVax Labs, Inc. (NASDAQ:GOVX ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Max Gadicke - Precision AQ, Investor Relations David Dodd - Chairman, President & Chief Executive Officer Mark Reynolds - Chief Financial Officer Conference Call Participants James Molloy - Alliance Global Partners Robert LeBoyer - Noble Capital Markets Jeffrey Kraws - Crystal Research Associates Operator Good afternoon. And welcome everyone to the GeoVax First Quarter 2025 Corporate Update Call.

GeoVax Labs, Inc. (GOVX) Q1 2025 Earnings Call Transcript

GeoVax Labs, Inc. (GOVX) Q4 2024 Earnings Call Transcript

GeoVax Labs, Inc. (NASDAQ:GOVX ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Max Gadicke - Precision AQ, Investor Relations David Dodd - Chairman, President & CEO Mark Reynolds - Chief Financial Officer Kelly McKee - Chief Medical Officer John Sharkey - Vice President, Business Development Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Robert LeBoyer - Noble Capital Markets Laura Suriel - Alliance Global Partners Operator Good afternoon. And welcome everyone to the GeoVax Fourth Quarter Full Year 2024 Corporate Update Call.

GeoVax Labs, Inc. (GOVX) Q4 2024 Earnings Call Transcript

查看新聞排名

價格圖表採用Lightweight Charts™實作